ANI Pharmaceuticals (ANIP)

[rgshredder]

I'm literally waiting for their nonexistent IR/media team to offer a POSSIBLE generic option towards the treatment of covid19 and having the day traders shoot this up 200-300%. These days any whiff of COVID19 prospect is enough to make a stock skyrocket. Hell, even the opinion of a CEO believing they have something without any data/facts to back them up is enough.....

You stumbled across EXCELLENT news that I would imagine would make this balloon...but here we are, discovering it ourselves.

We've had this since 2016. ANIP should be screaming it off the bloody rooftops at this point.

BAUDETTE, Minn., May 9, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of 50mg and 150mg fenofibrate capsules USP (the authorized generic of Lipofen®) in the ANI label. The distribution rights to fenofibrate were acquired earlier this year and, as previously announced, ANI had expected to transition these products to the ANI label in the second quarter of 2016. In 2015 the authorized generic for Lipofen® (fenofibrate capsules 50mg and 150mg USP) generated $21.9 million in revenues.

Arthur S. Przybyl, ANI's President and CEO stated, "We are pleased to have successfully transitioned the fenofibrate authorized generic to the ANI label on schedule."

About Lipofen® Capsules

Lipofen® (fenofibrate capsules) is a peroxisome proliferator receptor alpha (PPARa) activator indicated as an adjunct to diet: to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and for treatment of adult patients with severe hypertriglyceridemia.

RG